Beam Therapeutics (BEAM) Restored AAT Levels. Can BEAM-302 Deliver Clinical Benefit?

Gene-editing stocks fell Wednesday after Anthropic's AI model, Claude, identified a phage enzyme system with traits similar to CRISPR. CRISPR Therapeutics (CRSP) dropped 6%, Intellia (NTLA) 3%, Beam (BEAM) 6%, Prime Medicine (PRME) 12%, and Editas Medicine (EDIT) 8%. The discovery, called ART, links an RNA-to-DNA enzyme with repeating DNA and a mystery protein in bacteria-infecting viruses. CRISPR pioneer Feng Zhang called the finding intriguing but unproven.

Beam Global reported a 174% sequential revenue increase in Q2 2026, driven by backlog conversions. The company diversified into global energy, mobility, and intelligence sectors, with Europe matching U.S. revenue. Battery business gained traction in drones, robotics, and defense. Yuma relocation cut costs. Management expects margin expansion, targets AI data centers, and focuses on recurring revenue models. The company remains debt-free with a $100M credit line. Q2 gross margin improved by 30 pe

Beam Therapeutics (BEAM) reported a wider-than-expected Q2 2026 loss of $1.18 per share versus a $1.00 consensus loss. Revenue fell to $0.5 million, below a $30 million estimate, from $8.5 million a year earlier. Cash and securities were about $1.2 billion, supporting operations into mid-2029. Pipeline updates include risto-cel and BEAM-302 accelerated-approval plans.

Beam Therapeutics reported 2Q 2026 results in its 10-Q. Revenue was $0.5M, down from $8.5M a year earlier. Net loss attributable to Beam was $(122.7)M versus $(102.1)M, and diluted EPS was $(1.18) versus $(1.00). The company said BEACON risto-cel dosing is complete and a BLA is targeted for year-end 2026.

Beam Therapeutics Inc. (BEAM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation

Prime Medicine said it won a dispute with Beam Therapeutics over gene-editing technology rights related to AATD. Prime expects to start an AATD clinical trial this quarter, and its stock rose about 11% while Beam fell about 2%. Beam said it disagrees and may pursue further action, according to company statements.